Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1163108 Target Snapshot

STE20/SPS1-related proline-alanine-rich protein kinase · SINGLE PROTEIN · Homo sapiens

367Compounds
134Assays
5Approved Drugs
128.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9UEW8. Use UniProt Q9UEW8 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9UEW8 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats STE20/SPS1-related proline-alanine-rich protein kinase as ChEMBL target CHEMBL1163108, mapped to UniProt Q9UEW8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
STE20/SPS1-related proline-alanine-rich protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1163108
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9UEW8
STE20/SPS1-related proline-alanine-rich protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether STE20/SPS1-related proline-alanine-rich protein kinase is the right protein anchor across sources, using UniProt Q9UEW8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSTE20/SPS1-related proline-alanine-rich protein kinase
UniProt AccessionQ9UEW8
Component TypeProtein
Sequence Length545 aa

STE20/SPS1-related proline-alanine-rich protein kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as STE20/SPS1-related proline-alanine-rich protein kinase, mapped to UniProt Q9UEW8. Sequence length is 545 aa.

Mapped IDQ9UEW8
Review nameSTE20/SPS1-related proline-alanine-rich protein kinase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
2
Phase III
1
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC5045.0
EC501.0
KD82.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 7.84 IC50 14.4 Preclinical
CHEMBL5433617 7.46 IC50 35.0 Preclinical
CHEMBL4792789 7.3 IC50 50.0 Preclinical
CHEMBL4762099 6.96 IC50 110.0 Preclinical
CHEMBL388978 6.89 Kd 130.0 Preclinical
CHEMBL535 6.85 Kd 140.0 Approved
CHEMBL509032 6.82 Kd 150.0 Preclinical
CHEMBL4759888 6.62 IC50 240.0 Preclinical
CHEMBL4797256 6.58 IC50 260.0 Preclinical
CHEMBL1721885 6.37 Kd 430.0 Clinical
Distribution

pChEMBL Value Distribution

9
5.0
19
5.5
8
6.0
7
6.5
3
7.0
2
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

NINTEDANIB
CHEMBL502835
Approved 2014
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

134
Total Assays
44
Tested Compounds
1
Assay Types
Binding — 134 assays, 44 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 99 43 6.1
assay format 16 1 5.0
subcellular format 10 0
cell-based format 9 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine